PMID: 6171822Nov 1, 1981Paper

Core (2'-5')oligoadenylate and the cordycepin analog: inhibitors of Epstein--Barr virus-induced transformation of human lymphocytes in the absence of interferon

Proceedings of the National Academy of Sciences of the United States of America
P DoetschE E Henderson

Abstract

The 3'-deoxyadenosine (cordycepin) analog of (2'-5')oligo(A) [(2'-5')oligoadenylate with a triphosphate at the 5' end], synthesized enzymatically from cordycepin 5'-triphosphate in lysed rabbit reticulocytes or L-cell extracts was (i) inhibitory to translation in lysed rabbit reticulocytes and (ii) metabolically stable in extracts of either L cells or C85-5C lymphoblasts. The 5' dephosphorylated (core) (2'-5')oligo(A) and the core cordycepin analog can replace human fibroblast interferon in preventing the transformation of human lymphocytes after infection with Epstein--Barr virus B95-8 (EBV) as determined by the decreased incorporation of [3H]thymidine into cellular DNA and the inhibition of morphological transformation of EBV-infected lymphocytes. Whereas the naturally occurring core (2'-5')oligo(A) was cytotoxic to uninfected lymphocytes and proliferating lymphoblasts, the core cordycepin analog was not. Human leukocyte interferon was more effective than human fibroblast interferon in the inhibition of EBV-induced transformation of human umbilical cord lymphocytes and adult peripheral blood lymphocytes.

References

Jan 1, 1978·Endeavour·K Cantell
Oct 28, 1976·Nature·J S PaganoY T Huang
Nov 17, 1977·The New England Journal of Medicine·D T PurtiloW Edwards
Aug 1, 1979·The Journal of Pediatrics·W A Andiman
Sep 1, 1979·FEBS Letters·B R WilliamsI M Kerr
Oct 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·A SchmidtM Revel
Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·I M Kerr, R E Brown
Jun 1, 1976·Biochemical Pharmacology·W H Prusoff, D C Ward
Sep 1, 1965·Proceedings of the National Academy of Sciences of the United States of America·G J Todaro, S Baron
Feb 12, 1970·The New England Journal of Medicine·J C NiedermanR W McCollum
Nov 1, 1972·The Journal of General Virology·D J Moss, J H Pope
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A A CreaseyT C Merigan
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·I Krishnan, C Baglioni
Feb 1, 1980·Virology·A G Hovanessian, J N Wood
Apr 24, 1980·The New England Journal of Medicine·M S Hirsch, M N Swartz
Jun 5, 1980·The New England Journal of Medicine·J E RobinsonG Miller
Apr 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·D M Coen, P A Schaffer
Apr 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·L E Schnipper, C S Crumpacker
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A K DattaJ S Pagano

❮ Previous
Next ❯

Citations

Jan 1, 1992·The International Journal of Biochemistry·H C SchröderW E Müller
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·H CaillaJ Marti
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·L LaurenceH Cailla
Jan 20, 2011·Nucleic Acids Research·Jesper Buchhave PoulsenPia Møller Martensen
Sep 1, 1982·European Journal of Biochemistry·M Verhaegen-Lewalle, J Content
Sep 2, 1985·European Journal of Biochemistry·B BayardB Lebleu
Oct 15, 2013·Life Sciences·Hardeep S TuliDharambir Kashyap
Aug 30, 1983·Biochemical and Biophysical Research Communications·M S Chapekar, R I Glazer
Dec 1, 1983·Virology·D A EppsteinB B Schryver
Jun 6, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Joseph W HomanRobert J Suhadolnik
Apr 15, 1983·European Journal of Biochemistry·M C HaughI M Kerr
Jan 27, 2015·Oncoscience·Eunhyun RyuHyojeung Kang
Jul 25, 1983·FEBS Letters·O K SharmaB B Goswami
Mar 1, 1984·Infection and Immunity·J G GarnerR T Schooley
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Aussara PanyaPa-Thai Yenchitsomanus

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.